Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
2 hedge funds and large institutions have $169 invested in Oncternal Therapeutics, Inc. Common Stock in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
132% more capital invested
Capital invested by funds: $73 → $169 (+$96)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$96 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BNP Paribas Financial Markets
Paris,
France
| $96 | +$96 | +182 | New |
|
|
UBP
2
Union Bancaire Privee
Geneva 1,
Switzerland
| $73 | – | – | – |
|
ONCT Hedge Fund Activity: Q4 2025 in Review
2 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2025, worth a combined $169 — up 132% from $73 a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ONCT positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $96.
- 2 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2025, up from 1 in Q3 2025.
- Funds reported $169 of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2025, up 132% quarter-over-quarter.
- 1 fund opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2025 and 0 closed out, a net change of +1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2025 was BNP Paribas Financial Markets, an estimated $96 added.
Based on aggregated 13F filings for Q4 2025.